Ensho Therapeutics
Ensho Therapeutics, Inc.
Ensho Therapeutics is a clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases.
enshorx.com · Woodcliff Lake, NJ
Funding event
The round itself, as filedInferred stageSeries A
Sold of offered$7.3M of $15.6M
Filed2026-10-15
Days since filing29
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-10-02
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Danielle FryExecutive Officer
- Arash RassoulpourDirector
- Carlos SolorzanoDirector
- Eric PhamDirector
- Gerhard HagnDirector
- Neena Bitritto-GargDirector
- Tariq KassumDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-11-13UndersubscribedNot flagged$7.3M of $15.6M sold1.4 months since first sale
Prior raiseNot flagged$0 prior raiseprior filing 2026-02-09
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-10-160
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
Also raised in Health & bio
Same sector, 28 days to 2026-11-15OrcosaSeries A · $6.0M of $11.5M · Ewing, NJQuietChronicleBioPre-seed · $250K of $1.0M · Menlo Park, CAQuiet
103 rounds in Health & bio in the 28 days to 2026-11-12, against 122 in the 28 days before.